Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rechallenge of Rapidly Accelerated Fibrosarcoma B-type (BRAF) +/- Mitogen-activated Extracellular Signal-regulated Kinase (MEK) Inhibitors Following an Adverse Event in Patients With Cancer

NCT05080361 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT05080361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05080361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rechallenge of Rapidly Accelerated Fibrosarcoma B-type (BRAF) +/- Mitogen-activated Extracellular Signal-regulated Kinase (MEK) Inhibitors Following an Adverse Event in Patients With Cancer
Lead sponsor
University Hospital, Caen
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2011
Completion date
December 1, 2021
Enrollment
16,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer